Is diversity harmful?-Mixed-brand cardiac implantable electronic devices undergoing magnetic resonance imaging.


Journal

Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 22 03 2021
accepted: 09 07 2021
pubmed: 18 8 2021
medline: 26 4 2022
entrez: 17 8 2021
Statut: ppublish

Résumé

Many patients with cardiac implantable electronic devices (CIED) undergo magnetic resonance imaging (MRI); however, a relevant proportion have a CIED system that has not been classified as MRI-conditional because of generators and leads from different brands (mixed-brand group). The available data concerning the outcome of these mixed patients undergoing MRI is limited. A retrospective single center study, including all patients with CIEDs undergoing MRI between January 2013 until May 2020, was performed. Primary endpoints were defined as death or any adverse event necessitating hospitalization or CIED revision. Secondary endpoints were the occurrence of any sign for beginning device or lead failure or patient discomfort during MRI. A total of 227 MRI examinations, including 10 thoracic MRIs, were carried out in 158 patients, with 1-9 MRIs per patient. Of the patients 38 underwent 54 procedures in the mixed-brand group and 89 patients underwent 134 MRIs in the MRI-conditional group. Of the patients 31 were excluded since the MRI conditionality could not be determined. No primary endpoints occurred within the mixed-brand group but in 2.2% of the MRI-conditional group (p = 1.000), with 2 patients developing new atrial fibrillation during MRI, of whom one additionally had a transient CIED dysfunction. No secondary endpoints were met in the mixed-brand group compared to 3.4% in the MRI-conditional group (p = 0.554). No complications occurred in the excluded patients. The complication rate of CIED patients undergoing MRI was low. Patients with a mixed CIED system showed no signs of increased risk of adverse events compared to patients with MRI-conditional CIED systems.

Sections du résumé

BACKGROUND BACKGROUND
Many patients with cardiac implantable electronic devices (CIED) undergo magnetic resonance imaging (MRI); however, a relevant proportion have a CIED system that has not been classified as MRI-conditional because of generators and leads from different brands (mixed-brand group). The available data concerning the outcome of these mixed patients undergoing MRI is limited.
METHODS METHODS
A retrospective single center study, including all patients with CIEDs undergoing MRI between January 2013 until May 2020, was performed. Primary endpoints were defined as death or any adverse event necessitating hospitalization or CIED revision. Secondary endpoints were the occurrence of any sign for beginning device or lead failure or patient discomfort during MRI.
RESULTS RESULTS
A total of 227 MRI examinations, including 10 thoracic MRIs, were carried out in 158 patients, with 1-9 MRIs per patient. Of the patients 38 underwent 54 procedures in the mixed-brand group and 89 patients underwent 134 MRIs in the MRI-conditional group. Of the patients 31 were excluded since the MRI conditionality could not be determined. No primary endpoints occurred within the mixed-brand group but in 2.2% of the MRI-conditional group (p = 1.000), with 2 patients developing new atrial fibrillation during MRI, of whom one additionally had a transient CIED dysfunction. No secondary endpoints were met in the mixed-brand group compared to 3.4% in the MRI-conditional group (p = 0.554). No complications occurred in the excluded patients.
CONCLUSION CONCLUSIONS
The complication rate of CIED patients undergoing MRI was low. Patients with a mixed CIED system showed no signs of increased risk of adverse events compared to patients with MRI-conditional CIED systems.

Identifiants

pubmed: 34402991
doi: 10.1007/s00508-021-01924-w
pii: 10.1007/s00508-021-01924-w
pmc: PMC9023390
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

286-293

Informations de copyright

© 2021. The Author(s).

Références

Radiology. 2018 Nov;289(2):281-292
pubmed: 30251926
Pacing Clin Electrophysiol. 2017 May;40(5):467-475
pubmed: 28224629
Heart. 2011 Nov;97(22):1852-6
pubmed: 21873440
Pacing Clin Electrophysiol. 2002 Oct;25(10):1419-23
pubmed: 12418737
Neth Heart J. 2014 Jun;22(6):269-76
pubmed: 24733688
Heart Rhythm. 2011 Jan;8(1):65-73
pubmed: 20933098
JACC Clin Electrophysiol. 2017 Nov;3(11):1231-1239
pubmed: 29759618
Heart Rhythm. 2008 Mar;5(3):462-8
pubmed: 18313607
Europace. 2020 Feb 1;22(2):288-298
pubmed: 31995177
Circulation. 2006 Sep 19;114(12):1232-3
pubmed: 16982951
Circulation. 2007 Dec 11;116(24):2878-91
pubmed: 18025533
Pacing Clin Electrophysiol. 2001 Apr;24(4 Pt 1):489-95
pubmed: 11341087
Pacing Clin Electrophysiol. 2001 Feb;24(2):199-205
pubmed: 11270700
JACC Clin Electrophysiol. 2019 Aug;5(8):935-943
pubmed: 31439295
Heart Rhythm. 2015 Mar;12(3):540-544
pubmed: 25460173
Europace. 2013 Aug;15(8):1070-118
pubmed: 23801827
Eur Heart J. 2005 Feb;26(4):376-83; discussion 325-7
pubmed: 15618060
Europace. 2019 Aug 1;21(8):1220-1228
pubmed: 31131393
N Engl J Med. 2017 Feb 23;376(8):755-764
pubmed: 28225684
Sci Rep. 2019 Dec 3;9(1):18243
pubmed: 31796767
Am Heart J. 2013 Mar;165(3):266-72
pubmed: 23453091
Ann Intern Med. 2011 Oct 4;155(7):415-24
pubmed: 21969340
Pacing Clin Electrophysiol. 2021 Feb;44(2):360-372
pubmed: 33283900
Insights Imaging. 2017 Aug;8(4):405-418
pubmed: 28624970
J Cardiovasc Electrophysiol. 2017 Jul;28(7):806-810
pubmed: 28429537
Heart Rhythm. 2018 Jul;15(7):1001-1008
pubmed: 29458192
Heart Rhythm. 2018 Feb;15(2):218-225
pubmed: 29017930
Heart Rhythm. 2017 Jul;14(7):e97-e153
pubmed: 28502708
N Engl J Med. 2017 Dec 28;377(26):2555-2564
pubmed: 29281579
Pacing Clin Electrophysiol. 2005 Apr;28(4):326-8
pubmed: 15826268
Neth Heart J. 2018 Dec;26(12):584-590
pubmed: 30406601
Korean J Intern Med. 2019 Jan;34(1):99-107
pubmed: 29609452
Eur Heart J Cardiovasc Imaging. 2018 Sep 1;19(9):1051-1061
pubmed: 29048460
Abdom Radiol (NY). 2016 Mar;41(3):444-51
pubmed: 26940331
J Cardiovasc Magn Reson. 2011 Oct 27;13:63
pubmed: 22032338

Auteurs

Christoph Alexander König (CA)

3rd Department of Medicine, Cardiology and Intensive Care Medicine, Klinik Ottakring (Wilhelminenhospital), Montleartstraße 37, 1160, Vienna, Austria.
Medical University of Vienna, Vienna, Austria.

Florian Tinhofer (F)

3rd Department of Medicine, Cardiology and Intensive Care Medicine, Klinik Ottakring (Wilhelminenhospital), Montleartstraße 37, 1160, Vienna, Austria.

Thomas Puntus (T)

3rd Department of Medicine, Cardiology and Intensive Care Medicine, Klinik Ottakring (Wilhelminenhospital), Montleartstraße 37, 1160, Vienna, Austria.

Achim Leo Burger (AL)

3rd Department of Medicine, Cardiology and Intensive Care Medicine, Klinik Ottakring (Wilhelminenhospital), Montleartstraße 37, 1160, Vienna, Austria.

Nikolaus Neubauer (N)

Institute for Diagnostic and Interventional Radiology, Klinik Ottakring (Wilhelminenhospital), Vienna, Austria.

Herbert Langenberger (H)

Institute for Diagnostic and Interventional Radiology, Klinik Ottakring (Wilhelminenhospital), Vienna, Austria.

Kurt Huber (K)

3rd Department of Medicine, Cardiology and Intensive Care Medicine, Klinik Ottakring (Wilhelminenhospital), Montleartstraße 37, 1160, Vienna, Austria.
Medical School, Sigmund Freud University, Vienna, Austria.

Michael Nürnberg (M)

3rd Department of Medicine, Cardiology and Intensive Care Medicine, Klinik Ottakring (Wilhelminenhospital), Montleartstraße 37, 1160, Vienna, Austria.

David Zweiker (D)

3rd Department of Medicine, Cardiology and Intensive Care Medicine, Klinik Ottakring (Wilhelminenhospital), Montleartstraße 37, 1160, Vienna, Austria. david.zweiker@medunigraz.at.
Division of Cardiology, Medical University of Graz, Graz, Austria. david.zweiker@medunigraz.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH